Argenx Se · EURONEXT:ARGX
Argenx — Q3 2022 Earnings Presentation
19 slides from Argenx's earnings presentation, Oct 27, 2022
Slide 1: Together We Discover
Together We Discover Reaching Patients Through Immunology Innovation Third Quarter Financial Results and Business Update OCTOBER 27, 2022 1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or
Slide 3: Building a Leading Sustainable Immunology Company
Building a Leading Sustainable Immunology Company Driving innovation Global VYVGART launch mission with an Building Committed to entrepreneurial Company We our Patients $227M spirit and commitment Want to Work and in product revenues to a strong culture For Supporters in first three quarters Antibod
Slide 4: VYVGART Launch Shows Continued Momentum
VYVGART Launch Shows Continued Momentum Addressing the unmet Backed by solid science and need in gMG data > 2K patients on VYVGART globally $131M 3Q Net Product Revenues Significant physician and Broad coverage achieved patient demand 4
Slide 5: Multiple Data Readouts Expected in 2023
Multiple Data Readouts Expected in 2023 First Quarter 2023 Second Half 2023 5
Slide 6: Chronic Inflammatory Demyelinating Polyneuropathy ADHERE Trial
Chronic Inflammatory Demyelinating Polyneuropathy ADHERE Trial Confirm IgG autoantibody Assess efficacy & safety involvement efgartigimod vs placebo Treatment period Efficacy analysis based Identify patients with active CIDP Open-label Placebo-controlled on relapse (adjusted INCAT) Screening Run-in
Slide 7: Results Support Path Forward
ADVANCE-IV Phase 3 Results Support Path Forward • Statistically significant and clinically meaningful Primary endpoint met improvement in platelet counts over placebo • Fast and robust platelet count improvement over placebo Meaningful patient benefit observed • Ability for every other week dosing c
Slide 8: 51% of VYVGART Patients Showed Real-World Relevant Platelet Count Improvement
Per IWG criteria, 51% of VYVGART Patients Showed Real-World Relevant Platelet Count Improvement in Absence of Bleeding Clear Separation Between VYVGART and Placebo International Workgroup (IWG) Criteria Total patient population reflecting real-world treatment goals LS-Mean Platelet Count Change From
Slide 9: New Efgartigimod Translational Data
New Efgartigimod Translational Data Demonstrating our scientific leadership in FcRn biology, providing new insights into pathophysiology of autoimmune skin blistering diseases and potential role of FcRn blockade Maho-Vaillant M et al. FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cell
Slide 10: ARGX-117: Sweeping Antibody Designed to Target Unique Intervention in Complement
ARGX-117 Blocks C2 ARGX-117: Sweeping Antibody Classical Lectin Designed to Target Unique IgG C1 qrs IgM Mannose sugar MAS Ps MBL Intervention in Complement C4 C2 C3 convertase Targeting C2: C3a C3 C3b • Leaves alternative pathway intact against infection C5 convertase • Blocks all complement effect
Slide 11: ARGX-119: MuSK Agonist with Broad Potential in Neuromuscular Disease
ARGX-119: MuSK Agonist with Broad Potential in Neuromuscular Disease Oury, J., Zhang, W., Leloup, N. et al. Mechanism of disease and therapeutic rescue of Dok7 congenital myasthenia. Nature 595, 404–408 ARGX-119 ( ) induces AChR clustering, NMJ maturation and stabilization (2021). https://doi.org/10
Slide 12: Pipeline Growth Driven By Immunology Innovation Program
Pipeline Growth Driven By Immunology Innovation Program CLINICAL DEVELOPMENT LEADING ANTIBODY ENGINEERING TRANSLATIONAL BIOLOGY LABS Internal Value Creation Strategy External Value Creation Strategy Staten AgoMAb FIRST IN CLASS | UNIQUE DESIGN | MULTIPLE INDICATIONS ARGX-118 Dualyx (ARGX-116) (ARGX-
Slide 13: Global VYVGART Net Sales
Global VYVGART Net Sales 9 months ended (in millions $) Q1 FY22 Q2 FY22 Q3 FY22 Sept 30, 2022 US 21.2 73.2 124.1 218.5 Japan - 1.5 6.0 7.5 Europe - - 0.6 0.6 Distributor markets - 0.1 0.6 0.7 Total Product Net Sales 21.2 74.8 131.3 227.3 Strong quarter-over-quarter growth in global VYVGART revenues
Slide 14: Third Quarter 2022 Financial Results
Third Quarter 2022 Financial Results Three months ended Nine months ended September 30 September 30 (in millions of $) 2022 2021 2022 2021 Product net sales 131.3 - 227.3 - US 124.1 - 218.5 - Japan 6.0 - 7.5 - Europe 0.6 - 0.6 - Distributor Markets 0.6 - 0.7 - Collaboration revenue and other 15.2
Slide 15: Global gMG Launch Progressing
Global gMG Launch Progressing VYVGART SC BLA Filed United States Approved December 17, 2021 Japan Approvals expected throughout 2023: Gulf States Launched May 9, 2022 Canada (GenPharm) China Europe Central and Eastern Europe (Zai) Launched in Germany (Medison) September 1, 2022 Israel Global (Mediso
Slide 16: Executing on VYVGART Launch Priorities
Executing on VYVGART Launch Priorities Meeting our stakeholders where they are Empower Patients Best-in-Class Rapid HCP Enable to Demand Better Patient Adoption of Appropriate Support VYVGART Access MORE THAN Broad prescriber Broad coverage in 50% base; Shift to broad place; ~90% US policies adoptio
Slide 17: Differentiated Treatment Options for gMG Patients
Differentiated Treatment Options for gMG Patients SC efgartigimod ADAPT-NXT single injection Continuous Dosing Future Delivery Vehicles and Formulations (e.g., pre-filled syringe, Elektrofi, autoinjector) Eri, living with gMG 17 17
Slide 18: Reaching Patients With VYVGART
I completed my first cycle of “ Reaching VYVGART. I scored a “0” on the MG- “ ADL. It’s been nine weeks since I completed that first cycle, and I Patients With haven’t needed a subsequent cycle yet. VYVGART – VYVGART® Patient
Slide 19: Efgartigimod REVOLUTION
Efgartigimod A precision tool in autoimmunity targeting IgG autoantibodies Autoimmunity More than 50 Is Prime For autoimmune indications that are believed to be IgG-mediated REVOLUTION Need for new innovation Patients reliant on old tools (corticosteroids, broad immunosuppressants, IVIg) 19